Literature DB >> 18988165

Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study.

P Lanzetta1, F Furlan, L Morgante, D Veritti, F Bandello.   

Abstract

PURPOSE: To verify the efficacy of nonvisible micropulse diode laser irradiation in the treatment of central serous chorioretinopathy (CSC).
METHODS: Twenty-two patients with CSC for a total of 24 eyes with a disease duration longer than 3 months were included in a prospective study. Patients underwent Early Treatment Diabetic Retinopathy Study visual acuity (VA) examination, dilated ophthalmoscopy, fluorescein angiography, and optical coherence tomography before treatment and during follow- up. Treatment with a micropulse diode laser was given with a duty cycle of 15%. Multiple spots were placed over and adjacent to the area of retinal pigment epithelium leak or decompensation.
RESULTS: Mean follow-up was 14 months (range 3-36 months). Powers used ranged from 1 to 2 W (mean 1.35 W). Mean number of spots was 215 (range 90-400). Fourteen eyes were treated once, nine eyes received two to three treatments, and one eye had five treatments during a follow-up of 3 years. Subretinal fluid was resolved or improved in two third of cases 1 month after laser treatment, and in three-quarters at the end of follow-up. Mean retinal thickness was 328 microm, 197 microm, and 168 microm before, 1 month after irradiation, and at the end of follow-up, respectively. No evidence of RPE or retinal changes due to laser treatment were discernible in most of the eyes. Median VA was 20/32 (range 20/100-20/20) before treatment and 20/25 (range 20/200-20/20) at the end of the follow-up.
CONCLUSIONS: Nonvisible micropulse diode laser may have efficacy in the treatment of CSC. A randomized study with larger series is needed.

Entities:  

Mesh:

Year:  2008        PMID: 18988165     DOI: 10.1177/112067210801800613

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  45 in total

1.  Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy.

Authors:  M J Koss; I Beger; F H Koch
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

Review 2.  Retinal light toxicity.

Authors:  P N Youssef; N Sheibani; D M Albert
Journal:  Eye (Lond)       Date:  2010-10-29       Impact factor: 3.775

3.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

4.  Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome.

Authors:  N K Yadav; C Jayadev; A Mohan; P Vijayan; R Battu; S Dabir; B Shetty; R Shetty
Journal:  Eye (Lond)       Date:  2015-01-23       Impact factor: 3.775

5.  Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.

Authors:  Meltem Guzin Altınel; Banu Acikalin; Hasan Gunes; Gokhan Demir
Journal:  Lasers Med Sci       Date:  2021-01-07       Impact factor: 3.161

6.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

7.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

8.  Posterior to the ridge laser treatment for severe stage 3 retinopathy of prematurity.

Authors:  A L Ells; G A Gole; P Lloyd Hildebrand; A Ingram; C M Wilson; R Geoff Williams
Journal:  Eye (Lond)       Date:  2013-01-18       Impact factor: 3.775

9.  Severe visual loss secondary to central serous chorioretinopathy following prolonged immune suppression with oral prednisolone.

Authors:  A Harikrishnan; K Anderson; S Patra
Journal:  JRSM Short Rep       Date:  2010-09-15

Review 10.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.